Investor and Analyst Breakfast to be Held on Friday, May 12 at 7
a.m. EDT to Feature Data Presented at Meeting
LEXINGTON, Mass. and AMSTERDAM,
the Netherlands, April 24, 2017 (GLOBE NEWSWIRE) -- uniQure N.V.
(NASDAQ:QURE), a leading gene therapy company advancing
transformative therapies for patients with severe medical needs,
today announced that five abstracts have been accepted for
presentation at the American Society of Gene and Cell Therapy
(ASGCT) 20th Annual
Meeting held in Washington, D.C., May 10-13, 2017. Together with
their collaborators, members of uniQure's research and development
team will present data focused on progress in re-administration
protocols, gene therapy delivery systems and optimized vector
distribution technologies in two of uniQure's key programs,
hemophilia B and Huntington's disease. An investor and analyst
breakfast meeting featuring senior members of uniQure's research
and development team will be held on Friday, May 12 at 7 a.m.
"The data to be presented at the
ASGCT meeting demonstrate the development and validation of
uniQure's technologies to improve gene therapy as a therapeutic
approach, and supports our aim to rapidly bring new
disease-modifying therapies to patients with severe genetic
diseases," stated Matthew Kapusta, chief executive officer of
uniQure.
Harald Petry, Ph.D., chief
scientific officer at uniQure, added, "We are making strong
progress in advancing the preclinical development of AMT-130 in
Huntington's disease, and further enhancing AAV vector technology
and the potential for re-administration protocols, which continue
to provide compelling evidence of our modular platform."
Specific details on uniQure's
presentations at ASGCT include:
- Title: Novel AAV Vector
Reservoirs: peripheral Blood Cells and Hematopoietic
Progenitors. (collaborator presentation)
Oral Session Title: AAV Vector
Biology
Date and Time: Wednesday, May
10, 2017, 10:30 a.m. EDT
Location: Marriott Salon
1
- Title: Circulating
Anti-AAV5 Neutralizing Antibody Titers up to 1:1031 Do Not Affect
Liver Transduction Efficacy of AAV5 Vectors in Non-Human
Primates (Poster 198).
Poster Session
Title: Immunological Aspects of Gene Therapy and
Vaccines I
Session Date and
Time: Wednesday, May 10, 2017, 5:30 - 7:30 p.m.
EDT
Location: Hall A&B
South
- Title: Successful Repeated
Hepatic Gene Delivery in Non-Human Primates Achieved with AAV5 by
Use of Immune Adsorption (Poster 395).
Poster
Session Title: Immunological Aspects of Gene Therapy
and Vaccines II
Session Date and
Time: Thursday, May 11, 2017, 5:15 - 7:15 p.m.
EDT
Location: Hall A&B
South
- Title: AAV5-miHTT Gene
Therapy Demonstrates Broad Vector Distribution and Strong Mutant
Huntingtin Lowering in a Huntington's Disease Minipig
Model.
Oral Session
Title: Preclinical Progress Towards Therapies for
Neurologic Disorders
Date and Time: Friday, May 12,
2017, 4:30 p.m. EDT
Location: Delaware AB
- Title: Detection of AAV
Vector DNA and Transgene RNA in Liver Tissue by Fluorescent In Situ
Hybridization (Poster 567).
Poster Session Title: AAV
Vectors III
Session Date and Time: Friday,
May 12, 2017, 5:45 - 7:45 p.m. EDT
Location: Hall A&B
South
Investor and
Analyst Breakfast
uniQure management will host an investor and analyst breakfast
meeting featuring members of the research and development team to
review the data presented during ASGCT.
Date and
Time: |
|
Friday, May 12, 2017 at 7:00
am EDT |
Location: |
|
Omni Shoreham Hotel, The
Congressional Room, 2500 Calvert Street NW, Washington, DC. |
|
|
The Omni Shoreham hotel is
located directly across the conference venue. |
To request attendance at the
meeting, please RSVP to Investors@uniQure.com by May 5,
2017, as space is limited.
About
uniQure
uniQure is delivering on the promise of gene therapy - single
treatments with potentially curative results. We are leveraging our
modular and validated technology platform to rapidly advance a
pipeline of proprietary and partnered gene therapies to treat
patients with liver/metabolic, central nervous system and
cardiovascular diseases. www.uniQure.com
uniQure Forward-Looking
Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements include, but are not limited to, statements regarding
the development of our gene therapy product candidates.
Our actual results could differ materially from those anticipated
in these forward-looking statements for many reasons, including,
without limitation, risks associated with collaboration
arrangements, our and our collaborators' clinical development
activities, regulatory oversight, product commercialization and
intellectual property claims, as well as the risks, uncertainties
and other factors described under the heading "Risk Factors" in
uniQure's 2016 Annual Report on Form 10-K filed with the Securities
and Exchange Commission on March 15, 2017. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
uniQure Contacts:
Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone@uniQure.com